Comparable stake leader
B Group, Inc.
SEC ownership of NRX Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001719406.
Disclosed value leader
B Group, Inc.
Comparable rows
48/50
Latest evidence
30 Jun 2026
- Public ticker
- NRXP on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
B Group, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
48 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
B Group, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001719406
- Issuer location
- Wilmington, DE
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of NRX Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
B Group, Inc.
Disclosed value leader
B Group, Inc.
Comparable rows
48/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 13%
2 rows are not safely comparable across share classes.
13D/G row: B Group, Inc.
Showing 1-8 of 50 holder rows.
Quick read
B Group, Inc. leads the comparable SEC ownership view at 13%.
48 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens B Group, Inc.'s linked filing trail.
Comparable ownership
Top 5
B Group, Inc.
13%
Anson Funds Management LP
4.9%
VANGUARD CAPITAL MANAGEMENT LLC
4.6%
AMERIPRISE FINANCIAL INC
2.6%
BALYASNY ASSET MANAGEMENT L.P.
2.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| B Group, Inc. |
13F
13D/G
3/4/5
Company · The B Group, Inc. · 10%+ Owner
|
13%
from 13D/G
|
$16,735,327
4,091,767 shares
|
— | 30 Jun 2026 |
| Anson Funds Management LP |
13D/G
|
4.9%
|
$3,855,556
1,736,737 shares
|
+$292,512 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
4.6%
|
$6,618,270
1,618,159 shares
|
— | 30 Jun 2026 |
| AMERIPRISE FINANCIAL INC |
13F
Company
|
2.6%
|
$3,798,498
928,728 shares
|
— | 30 Jun 2026 |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
Company
|
2.5%
|
$3,655,904
893,864 shares
|
— | 30 Jun 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.9%
|
$2,781,376
680,043 shares
|
— | 30 Jun 2026 |
| AdvisorShares Investments LLC |
13F
Company
|
1.9%
|
$2,695,384
659,018 shares
|
— | 30 Jun 2026 |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
Company
|
1.3%
|
$1,858,570
454,418 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 17 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to NRX Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
B Group, Inc.
Net 12M change
$0
Latest report
27 Jan 2026
Recent insider transactions for NRX Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Joseph M. Casper | NRXP | Stock Option (right to buy) | Award | 100,000 | 100,000 | 27 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.